您的位置: 专家智库 > >

国家自然科学基金(90813025)

作品数:3 被引量:4H指数:1
相关作者:姜丹王应杨晓虹孙薇綦辉更多>>
相关机构:北京大学军事医学科学院吉林大学更多>>
发文基金:国家自然科学基金北京市自然科学基金国家科技重大专项更多>>
相关领域:理学生物学医药卫生更多>>

文献类型

  • 3篇中文期刊文章

领域

  • 1篇生物学
  • 1篇医药卫生
  • 1篇理学

主题

  • 2篇CCR4
  • 1篇炎症
  • 1篇受体
  • 1篇趋化
  • 1篇趋化因子
  • 1篇趋化因子受体
  • 1篇转染
  • 1篇转染细胞
  • 1篇拮抗剂
  • 1篇哌嗪
  • 1篇细胞
  • 1篇基因
  • 1篇基因转染
  • 1篇基因转染细胞
  • 1篇过敏
  • 1篇过敏性
  • 1篇过敏性炎症
  • 1篇NCT
  • 1篇PHT
  • 1篇TARC

机构

  • 1篇北京大学
  • 1篇吉林大学
  • 1篇军事医学科学...

作者

  • 1篇李松
  • 1篇巩宏伟
  • 1篇肖军海
  • 1篇綦辉
  • 1篇孙薇
  • 1篇杨晓虹
  • 1篇王应
  • 1篇姜丹

传媒

  • 1篇高等学校化学...
  • 1篇Scienc...
  • 1篇Journa...

年份

  • 1篇2013
  • 1篇2011
  • 1篇2010
3 条 记 录,以下是 1-3
排序方式:
Rat CC chemokine receptor 4 is the functional homologue of human CC chemokine receptor 4 and can interact with human CCL17 and CCL22
2010年
Human CCL17/TARC (hCCL17) and CCL22/MDC (hCCL22) interact with their receptor CCR4, playing pivotal roles in various Th2 cell-dominant diseases. Rat Ccl17, Ccl22 and Ccr4 share 63.4%, 65.2% and 87.5% homology at the amino acid level, respectively, compared with their human homologues. Rat Ccl22 has been demonstrated to interact with rat Ccr4. However, it is not known whether rat Ccl17 is a functional ligand for rat Ccr4 and whether rat Ccr4 can interact with hCCL17 and hCCL22. In this study, we cloned rat Ccl17 and Ccr4 cDNA from rat thymus and expressed the recombinant rat Ccl17. The binding assay indicated rat Ccl17 could saturably bind rat Ccr4, and this binding could be competitively inhibited by unlabeled rat Cc17, hCCL17 or hCCL22. Both rat and human CCL17 or CCL22 could induce the chemotactic migration and calcium mobilization in rat Ccr4-transfected cells. They could also desensitize each other’s effect on chemotaxis and calcium mobilization. Furthermore, both rat Ccl17 and hCCL17 could induce significant receptor internalization in rat Ccr4-EGFP transfected cells. These results demonstrated the conserved CCL17/CCR4 interaction in rats and the further cross-species interaction of rat Ccr4 with hCCL17 and hCCL22. Likewise, they provided the molecular basis for the investigation of physiological and pharmacological roles of CCR4, its ligands, and their antagonists in rat disease models.
TIAN LinJie1,2, QI Hui1,2, XIE Yuan1,2, ZHANG YingMei1,2, ZHANG WenJuan1,2, SUN XiangYu1,2, WANG Ying1,2 & MA DaLong1,2 1 Laboratory of Medical Immunology, School of Basic Medical Science, Peking University Health Science Center, Beijing 100191, China
关键词:趋化因子受体基因转染细胞
哌嗪嘧啶类CCR4拮抗剂的设计、合成及生物活性被引量:3
2013年
基于对已报道的CCR4拮抗剂的构效关系分析,设计并合成了一系列哌嗪嘧啶类化合物.采用细胞趋化抑制实验测试了合成化合物的体外活性,其中化合物8a的活性优于目前报道的活性最好的化合物BMS-397;在小鼠鼻炎模型中,化合物8a以极低的剂量达到了布地奈德(鼻炎临床治疗药物)的治疗效果.采用毛细管电泳法测得化合物8a与CCR4 N端40肽的结合常数为(3.6179±0.5976)×104L/mol.
巩宏伟綦辉孙薇姜丹肖军海杨晓虹王应李松
关键词:TARCMDC过敏性炎症
Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis被引量:1
2011年
Abstract CC chemokine receptor 4 (CCR4) is a kind of G-protein-coupled receptor, which plays a pivotal role in allergic inflammation. The interaction between 2-(2-(4-chloro-phenyl)-5-{[(naphthalen-1- ylmethyl)-carbamlyl]-methyl-4-oxo-thiazolidin-3-yl)-N-(3-morpholin-4-yl-propyi)-acetamide (S009) and the N-terminal extracellular tail (ML40) of CCR4 has been validated to be high affinity by capillary zone electrophoresis (CZE).The S009 is a known CCR4 antagonist. Now, a series of new thiourea derivatives have been synthesized. Compared with positive control S009, they were screened using ML40 as target by CZE to find some new drugs for allergic inflammation diseases. The synthesized compounds XJH-5, XJH-4, XJH-17 and XJH-1 displayed the interaction with ML40, but XJH-9, XJH-10, XJH-I 1, XJH-12, XJH-13, XJH-14, XJH-3, XJH-8, XJH-6, XJH-7, XJH-15, XJH-16 and XJH-2 did not bind to ML40. Both qualification and quantification characterizations of the binding were determined. The affinity of the four compounds was valued by the binding constant, which was similar with the results of chemotactic experiments. The established CEZ method is capable of sensitive and fast screening for a series of lactam analogs in the drug discovery for allergic inflammation diseases.
Zhe SunLin-Jie TianQian LinXiao-Mei LingJun-Hai XiaoYing Wang
共1页<1>
聚类工具0